These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10217310)

  • 1. Cellular uptake and release of two contrasting iron chelators.
    Cable H; Lloyd JB
    J Pharm Pharmacol; 1999 Feb; 51(2):131-4. PubMed ID: 10217310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
    Hoyes KP; Porter JB
    Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two isomeric beta-d-glucosiduronic acids derived from 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rat liver homogenate incubates.
    Liu DY; Liu ZD; Piyamongkol S; Lu SL; Hider RC
    J Pharm Pharmacol; 2002 Jul; 54(7):951-7. PubMed ID: 12162714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
    Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S
    Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
    J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
    Porter JB; Singh S; Hoyes KP; Epemolu O; Abeysinghe RD; Hider RC
    Adv Exp Med Biol; 1994; 356():361-70. PubMed ID: 7887242
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.
    Hershko C; Link G; Pinson A; Peter HH; Dobbin P; Hider RC
    Blood; 1991 May; 77(9):2049-53. PubMed ID: 2018841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
    Epemolu OR; Singh S; Hider RC; Damani LA
    Drug Metab Dispos; 1992; 20(5):736-41. PubMed ID: 1358580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat.
    Lu SL; Gosriwatana I; Liu DY; Liu ZD; Mallet AI; Hider RC
    Drug Metab Dispos; 2000 Aug; 28(8):873-9. PubMed ID: 10901694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pinocytosis of 125I-labelled poly(vinylpyrrolidone), [14C]sucrose and colloidal [198Au]gold by rat yolk sac cultured in vitro.
    Roberts AV; Williams KE; Lloyd JB
    Biochem J; 1977 Nov; 168(2):239-44. PubMed ID: 597271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that desferrioxamine cannot enter cells by passive diffusion.
    Lloyd JB; Cable H; Rice-Evans C
    Biochem Pharmacol; 1991 May; 41(9):1361-3. PubMed ID: 2018567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
    Choudhury R; Singh S
    Drug Metab Dispos; 1995 Mar; 23(3):314-20. PubMed ID: 7628295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
    Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
    Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.
    Hamilton KO; Stallibrass L; Hassan I; Jin Y; Halleux C; Mackay M
    Br J Haematol; 1994 Apr; 86(4):851-7. PubMed ID: 7918082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
    Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.
    Soteriadou K; Papavassiliou P; Voyiatzaki C; Boelaert J
    J Antimicrob Chemother; 1995 Jan; 35(1):23-9. PubMed ID: 7768775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of microparticles by rat visceral yolk sac.
    Pratten MK; Lloyd JB
    Placenta; 1997 Sep; 18(7):547-52. PubMed ID: 9290150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
    Singh S; Epemolu RO; Dobbin PS; Tilbrook GS; Ellis BL; Damani LA; Hider RC
    Drug Metab Dispos; 1992; 20(2):256-61. PubMed ID: 1352218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
    Jin Y; Baquet A; Florence A; Crichton RR; Schneider YJ
    Biochem Pharmacol; 1989 Oct; 38(19):3233-40. PubMed ID: 2818622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
    Huang XP; Thiessen JJ; Spino M; Templeton DM
    Int J Hematol; 2010 Apr; 91(3):401-12. PubMed ID: 20213118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.